Ocugen (OCGN) Free Cash Flow (2014 - 2026)
Ocugen (OCGN) reported Free Cash Flow of -$21.8 million for Q1 2026, down 12.53% on a YoY basis from -$24.9 million in Q1 2025, and down 54.31% quarter-over-quarter from -$14.1 million in Q4 2025.
Ocugen (OCGN) Free Cash Flow (2014 - 2026) Analysis & Trends
Ocugen has reported Free Cash Flow for 13 years, with the latest figure at -$21.8 million in Q1 2026.
- For the quarter ending Q1 2026, Free Cash Flow fell 12.53% year-over-year to -$21.8 million; the trailing twelve-month figure through Mar 2026 stood at -$59.6 million (down 10.46% YoY), and the FY2025 full-year result was -$57.1 million, down 25.53% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$21.8 million, down from -$14.1 million in the prior quarter.
- The five-year high for Free Cash Flow was -$10.4 million in Q4 2024, with the low at -$21.8 million in Q1 2026.
- Historically, Free Cash Flow has averaged -$15.2 million across 5 years, with a median of -$14.1 million in 2025.
- Annual changes were most pronounced in 2022 — Free Cash Flow slumped 182.77% — and 2024, when it jumped 44.76%.
- Ocugen's Free Cash Flow stood at -$15.4 million in 2022, then rose by 8.89% to -$14.0 million in 2023, then grew by 26.01% to -$10.4 million in 2024, then sank by 36.14% to -$14.1 million in 2025, then sank by 54.31% to -$21.8 million in 2026.
- The last three Free Cash Flow figures came in at -$21.8 million (Q1 2026), -$14.1 million (Q4 2025), and -$12.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.49 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.29 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 63,220.27 |
| 10 | Ocugen | 411.07 Mn | 411.07 Mn | - | -21.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -21.80 Mn |
| Mar 31, 2026 | -21.80 Mn |
| Dec 31, 2025 | -14.13 Mn |
| Dec 31, 2025 | -14.13 Mn |
| Sep 30, 2025 | -12.88 Mn |
| Sep 30, 2025 | -12.88 Mn |
| Jun 30, 2025 | -10.77 Mn |
| Jun 30, 2025 | -10.77 Mn |
| Mar 31, 2025 | -19.37 Mn |
| Mar 31, 2025 | -19.37 Mn |
| Dec 31, 2024 | -10.38 Mn |
| Dec 31, 2024 | -10.38 Mn |
| Sep 30, 2024 | -11.78 Mn |
| Sep 30, 2024 | -11.78 Mn |
| Jun 30, 2024 | -12.41 Mn |
| Jun 30, 2024 | -12.41 Mn |
| Mar 31, 2024 | -10.97 Mn |
| Mar 31, 2024 | -10.97 Mn |
| Dec 31, 2023 | -14.02 Mn |
| Dec 31, 2023 | -14.02 Mn |